Thymosin Alpha-1

Key benefits

What to expect

Based on community reports and published research. Individual results vary significantly.

Vendor ratings are based on community feedback and are not endorsements. Always verify third-party certificates of analysis (CoA) and check your local regulations before purchasing.

Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced by the thymus gland. The thymus is responsible for T-cell maturation - a critical component of adaptive immunity. Thymic output declines sharply after puberty (thymic involution), correlating with age-related immune decline. Tα1 was first isolated by Dr. Allan Goldstein in 1972 and has been developed commercially as Zadaxin by SciClone Pharmaceuticals. It is approved in over 30 countries (including several in Asia and South America) for chronic hepatitis B, hepatitis C, and as an immune adjuvant. It has also been studied for its potential in cancer immunotherapy and post-COVID immune recovery.

How it works

Tα1 modulates immune function by promoting T-cell maturation, differentiation, and activation. It enhances dendritic cell function (key antigen-presenting cells), increases natural killer cell activity, and modulates cytokine expression toward a balanced Th1/Th2 response. Importantly, it is immunomodulatory rather than immunostimulatory - it enhances underactive immune responses without overstimulating already active ones. This makes it suitable for both immunocompromised patients and those with autoimmune tendencies.

Side effects

Research history

The aging thymus

The thymus gland begins shrinking after puberty in a process called thymic involution. By age 50, the thymus has lost approximately 80% of its functional tissue. This directly impacts T-cell production and immune surveillance. Thymosin Alpha-1 supplementation aims to compensate for reduced thymic output by providing the peptide that the thymus would normally produce. This rationale is similar to GHK-Cu supplementation (replacing what declines with age) and is supported by clinical data showing improved immune markers in elderly patients.

Recommended products

Hand-picked for this compound. Ships via Amazon 🇺🇸

References

1. [1]Goldstein AL, et al. "Thymosin alpha 1: from bench to bedside." Annals of the New York Academy of Sciences, 2007.
2. [2]Garaci E, et al. "Thymosin alpha 1 in the treatment of cancer." International Journal of Immunopharmacology, 2000.
3. [3]Tuthill C, et al. "Thymosin alpha 1 - past clinical experience and future promise." Annals of the New York Academy of Sciences, 2010.

Frequently asked questions

Related peptides